Aspira Womens Health Inc (AWHL)

Currency in USD
0.209
-0.005(-2.34%)
Closed·
AWHL Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
AWHL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.1850.215
52 wk Range
0.0201.390
Key Statistics
Prev. Close
0.209
Open
0.211
Day's Range
0.185-0.215
52 wk Range
0.02-1.39
Volume
118.64K
Average Volume (3m)
143.74K
1-Year Change
-81.67%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AWHL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Aspira Womens Health Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Strong Buy

Aspira Womens Health Inc Company Profile

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company’s products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1’s high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OVAinform, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and ENDOinform for the identification of endometriosis. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force; Aspira Synergy platform; and with marketing and distribution agreements. It has a research agreement with Harvard’s Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs, and proteins; and a strategic alliance agreement with Quest Diagnostics Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women’s Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.

Aspira Womens Health Inc SWOT Analysis


Diagnostic Innovato
Aspira Women's Health leads in ovarian cancer diagnostics with OvaSuite and OvaWatch, positioning itself in a growing market for advanced women's health tools
Financial Hurdles
Despite revenue challenges and cash burn concerns, AWH shows promise with increasing test volumes and improving Average Selling Prices
Regulatory Milestones
New York State approval for OvaWatch opens significant market opportunities, potentially catalyzing growth and expansion into other regions
Analyst Outlook
Cantor Fitzgerald maintains a $3.00 price target, reflecting cautious optimism amid AWH's efforts to balance growth with operational efficiency
Read full SWOT analysis

Aspira Womens Health Inc Earnings Call Summary for Q3/2024

  • OvaSuite revenue up 2% YoY to $2.3M in Q3 2024; test volume grew 4% despite challenges
  • $10M ARPA-H award for ENDOinform development; New York State approval for OvaWatch
  • R&D expenses down 9%, sales/marketing up 26%; gross margins improved to 60%
  • Collaboration with Dana-Farber and Harvard enhances early-stage ovarian cancer detection
  • Focus on expanding ovarian cancer portfolio and commercial capabilities; positive outlook for women's health investments
Last Updated: 14/11/2024, 21:42
Read Full Transcript

Compare AWHL to Peers and Sector

Metrics to compare
AWHL
Peers
Sector
Relationship
P/E Ratio
−0.7x−3.8x−0.5x
PEG Ratio
−0.01−0.190.00
Price/Book
−124.2x3.3x2.6x
Price / LTM Sales
0.8x2.0x3.3x
Upside (Analyst Target)
-80.3%43.5%
Fair Value Upside
Unlock8.0%6.9%Unlock

Earnings

Latest Release
May 19, 2025
EPS / Forecast
-0.09 / -0.22
Revenue / Forecast
2.28M / --
EPS Revisions
Last 90 days

AWHL Income Statement

People Also Watch

0.95
KLTO
-3.06%
1.42
WOLF
-5.33%
0.71
AEON
-2.72%
79.44
MRK
-1.67%

FAQ

What Stock Exchange Does Aspira Womens Health Trade On?

Aspira Womens Health is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Aspira Womens Health?

The stock symbol for Aspira Womens Health is "AWHL."

What Is the Aspira Womens Health Market Cap?

As of today, Aspira Womens Health market cap is 7.46M.

What Is Aspira Womens Health's Earnings Per Share (TTM)?

The Aspira Womens Health EPS (TTM) is -0.62.

From a Technical Analysis Perspective, Is AWHL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Aspira Womens Health Stock Split?

Aspira Womens Health has split 2 times.

How Many Employees Does Aspira Womens Health Have?

Aspira Womens Health has 66 employees.

What is the current trading status of Aspira Womens Health (AWHL)?

As of 07 Aug 2025, Aspira Womens Health (AWHL) is trading at a price of 0.21, with a previous close of 0.21. The stock has fluctuated within a day range of 0.19 to 0.22, while its 52-week range spans from 0.02 to 1.39.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.